PNA Derivatives Inhibit SNAP25 Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering botulinum toxin A for cosmetic use face challenges in achieving localized, deep muscle penetration without invasive formulations, and existing oligonucleotides like antisense phosphorothioate oligonucleotides suffer from poor cell permeability and toxicity issues.
Innovation Solution
A peptide nucleic acid (PNA) derivative is developed, represented by Formula I, which is designed to complementarily bind to the 3' splice site of the SNAP25 pre-mRNA, inducing exon skipping and inhibiting the functional activity of the SNAP25 protein, thereby mimicking the effects of botulinum toxin A while avoiding invasive delivery methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense phosphorothioate oligonucleotides are used to inhibit SNAP25 protein, then the functional activity is reduced, but cell permeability is poor and toxicity increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of oligonucleotides from phosphorothioate backbone to peptide nucleic acid (PNA) backbone. This structural parameter change fundamentally alters the properties: PNA maintains sequence-specific binding capability for SNAP25 inhibition while simultaneously improving cell permeability and reducing toxicity, thus resolving the contradiction between inhibition efficacy and harmful effects
Solution Approach 2:
The patent employs composite materials by designing PNA derivatives with specific amino acid sequences that combine nucleic acid base-pairing capabilities with peptide-like cellular penetration properties. The PNA structure integrates the functional advantages of both nucleic acids (specific binding) and peptides (cell permeability), creating a composite molecule that overcomes the limitations of phosphorothioate oligonucleotides
2Reliability
If botulinum toxin A is delivered for cosmetic use, then muscle activity is reduced, but invasive delivery methods are required for deep muscle penetration
Solution Approach 1:
The patent uses PNA as an intermediary molecule that mimics the functional effect of botulinum toxin A without requiring its invasive delivery. The PNA binds to SNAP25 pre-mRNA and induces exon skipping, thereby inhibiting SNAP25 protein production and achieving muscle relaxation similar to botulinum toxin, but through a non-invasive topical application route
Solution Approach 2:
The patent creates a functional copy of botulinum toxin A's effect using PNA technology. Instead of delivering the actual toxin protein through invasive methods, the PNA copies the downstream effect by inhibiting SNAP25 synthesis at the genetic level, achieving the same therapeutic outcome through a safer, non-invasive mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PNA derivative effectively inhibits SNAP25 protein expression in cells and skin upon topical administration, offering a safer and more effective alternative to traditional botulinum toxin injections by achieving the desired therapeutic effects without the need for deep muscle penetration.
Implementation Method 1
designed to complementarily bind to the 3' splice site of the SNAP25 pre-mRNA
Data Source
AI summary
Provided are peptide nucleic acid derivatives targeting a 3′ splice site of the human SNAP25 pre-mRNA. The peptide nucleic acid derivatives potently induce at least a splice variant of the human SNAP25 mRNA in cells, and are useful to safely treat dermatological indications or conditions involving the expression of the human SNAP25 protein by topical administration.